Journal Options HIV
Course Directors: Joseph J. Eron, Jr., MD, Andrew R. Zolopa, MD, William G. Powderly, MD
Recent Articles
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.
Sabin CA, Worm SW, Weber R, et al, for the D:A:D Study Group.
Lancet. 2008;371:1417-1426.
Abstract
Class-sparing regimens for initial treatment of HIV-1 infection.
Riddler SA, Haubrich R, DiRienzo AG, et al.
New Engl J Med. 2008;358:2095-2106.
Abstract
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.
Emery S, Neuhaus JA, Phillips AN, et al, for the SMART Study Group.
J Infect Dis. 2008;197:1133-1144.
Abstract
Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts.
Ribaudo HJ, Kuritzkes DR, Lalama CM, et al.
J Infect Dis. 2008;197:1006-1010.
Abstract
Durability and Outcome of Initial Antiretroviral Treatments Received during 2000-2005 by Patients in the Swiss HIV Cohort Study.
Vo TT, Ledergerber B, Keiser O, et al.
J Infect Dis. 2008;197:1685-1694.
Abstract
Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003.
Patel P, Hanson DL, Sullivan PS, et al.
Ann Intern Med. 2008;148:728-736.
Abstract
Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study.
McComsey GA, Re VL 3rd, O'Riordan M, et al.
Clin Infect Dis. 2008;46:1290-1296.
Abstract
Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.
Lundgren JD, Babiker A, El-Sadr W, et al, for the SMART Study Group.
J Infect Dis. 2008;197:1145-1155.
Abstract
Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors.
Bani-Sadr F, Lapidus N, Bedossa P, et al.
Clin Infectious Dis. 2008;46:768-774.
Capsule Summary Expert Commentary Abstract Slides
Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
Delfraissy JF, Flandre P, Delaugerre C, et al.
AIDS. 2008;22:385-393.
Capsule Summary Expert Commentary Abstract Slides
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
|